Slade Health has been named as the sole supplier of sterile compounded Antibiotics, Chemotherapy and Analgesics for all South Australian public hospitals. This follows almost three years of providing chemotherapy compounding services to these hospitals.
The agreement, which was awarded following a public tender process, will see Slade service up to 26 public hospitals across the state across Adelaide, Ceduna, Port Augusta and other regional areas.
CEO David Slade said that Slade welcomed the opportunity to extend its current compounding service in South Australia.
“This is an acknowledgement of the exceptional service that Slade Health has been providing to hospitals in South Australia. We spend a great deal of time ensuring we understand and deliver on South Australian Hospital requirements. In addition, being a full-service compounder means we can offer our customers the complete range of sterile compounded medications from our world-class licensed sterile facilities.”
“We have an unwavering commitment to patient access and product quality. Our strong network of TGA-licensed facilities, combined with exceptional customer service, position us to deliver state-wide contracts in addition to servicing more than 200 hospitals located across all Australian states, in both regional and metropolitan areas,” he said.
Mr Slade said that delivering an effective compounding service also meant reduced waiting times for patients. “The patient is at the centre of everything we do at Slade. We are delighted to partner with SA Health to deliver excellent care to patients in South Australia.”
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into Singapore, Mainland China, Hong Kong and New Zealand.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.
由於內容尚未被翻譯成中文，您將會被轉到英文頁面。